Hepatocellular carcinoma: From gene to public health

Journal of the National Cancer Institute

Volumn 89, Issue 24, 1997, Pages 1844-1851

  Montesano, R ^a   Hainaut, P ^a   Wild, C P ^b  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN;

AFRICA; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER PREVENTION; CANCER RISK; CHINA; DIET; GENE MUTATION; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; MOZAMBIQUE; PREVALENCE; PRIMARY PREVENTION; REVIEW; SOUTHEAST ASIA;

EID: 0031442701     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.24.1844     Document Type: Review

References (93)

1. Murray CJ, Feachem RG. Adult mortality in developing countries. Trans R Soc Trop Med Hyg 1990;84:1-2.
2. Kane M. Global programme for control of hepatitis B infection. Vaccine 1995;13 Suppl 1:S47-9.
3. Tomatis L. Cancer: causes, occurrence and control. In: IARC Scientific Publications No. 100. Lyon (France): IARC, 1990.
4. Some naturally occurring substances: food items and constituents, heterocyclic aromatic amines and mycotoxins. IARC Monogr Eval Carcinog Risks Hum, vol 56. Lyon (France): IARC, 1996.
5. Wild CP, Jansen LA, Cova L, Montesano R. Molecular dosimetry of aflatoxin exposure: contribution to understanding the multifactorial etiopathogenesis of primary hepatocellular carcinoma with particular reference to hepatitis B virus. Environ Health Perspect 1993;99:115-22.
6. Groopman JD. Molecular dosimetry methods for assessing human aflatoxin exposures. In: Eaton DA, Groopman JD, editors. The toxicology of aflatoxins: human health, veterinary and agricultural significance. New York: Academic Press, 1994:259-79.
7. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa [see comments]. Nature 1991;350:429-31.
8. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991; 350:427-8.
9. Hall AJ, Wild CP. Epidemiology of aflatoxin related disease. In: Eaton DA, Groopman JD, editors. The toxicology of aflatoxins: human health, veterinary and agricultural significance. New York: Academic Press, 1994: 233-58.
10. Wild CP, Pisani P. Carcinogen-DNA and -protein adducts in molecular epidemiology. In: Toniolo P, Boffetta P, Shuker D, Rothman N, Hulka B, Pearce N, editors. Application of biomarkers to cancer epidemiology. IARC Sci Publ 1997;142:143-58.
11. Qian GS, Ross RK, Yu MC, Yuan JM, Gao YT, Henderson BE, et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev 1994;3:3-10.
12. Wang JS, Qian GS, Zarba A, He X, Zhu YR, Zhang BC, et al. Temporal patterns of aflatoxin-albumin adducts in hepatitis B surface antigen-positive and antigen-negative residents of Daxin, Qidong County, People's Republic of China. Cancer Epidemiol Biomarkers Prev 1996;5:253-61.
13. Wild CP, Garner RC, Montesano R, Tursi F. Aflatoxin Bl binding to plasma albumin and liver DNA upon chronic administration to rats. Carcinogenesis 1986;7:853-8.
14. Wild CP, Jiang YZ, Allen SJ, Jansen LA, Hall AJ, Montesano R. Aflatoxin-albumin adducts in human sera from different regions of the world. Carcinogenesis 1990;11:2271-4.
15. Hainaut P, Soussi T, Shomer B, Hollstein M, Greenblatt M, Hovig E, et al. Database of p53 gene somatic mutations in humans tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res 1997;25: 151-7.
16. Esteve A, Sorlie T, Martel-Planche G, Hollstein M, Kusters I, Lewalter J, et al. Screening for p53 gene mutations in archived tumors of workers occupationally exposed to carcinogens: examples from analysis of bladder tumors. J Occup Environ Med 1995;37:59-68.
17. Harris CC. Chemical and physical carcinogenesis: advances and perspectives for the 1990s. Cancer Res 1991;51(18 Suppl):5023s-5044s.
18. Harris CC. The 1995 Walter Hubert Lecture - molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumour-suppressor gene. Br J Cancer 1996;73:261-9.
19. Soini Y, Chia SC, Bennett WP, Groopman JD, Wang JS, DeBenedetti VM, et al. An aflatoxin-associated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico. Carcinogenesis 1996;17:1007-12.
20. Wang LY, Hatch M, Chen CJ, Levin B, You SL, Lu SN, et al. Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan. Int J Cancer 1996;67:620-5.
21. 1 exposure in hepatocellular carcinoma patients from Thailand. Int J Cancer 1993;53:51-5.
22. Hsieh DP, Atkinson DN. Recent aflatoxin exposure and mutation at codon 249 of the human p53 gene: lack of association. Food Addit Contam 1995; 12:421-4.
23. Eaton DL, Gallagher EP. Mechanisms of aflatoxin carcinogenesis. Annu Rev Pharmacol Toxicol 1994;34:135-72.
24. 1 in woodchucks. Cancer Res 1995;55:3318-30.
25. Sell S, Hunt JM, Dunsford HA, Chisari FV. Synergy between hepatitis B virus expression and chemical hepatocarcinogens in transgenic mice. Cancer Res 1991;51:1278-85.
26. Hepatitis viruses. IARC Monogr Eval Carcinog Risks Hum, vol 59. Lyon (France): IARC, 1994.
27. Alcohol drinking. IARC Monogr Eval Carcinog Risks Hum, vol 44. Lyon (France): IARC, 1988.
28. Hagen TM, Huang S, Curnutte J, Fowler P, Martinez V, Wehr CM, et al. Extensive oxidative DNA damage in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma. Proc Natl Acad Sci U S A 1994;91:12808-12.
29. Bartsch H, Barbin A, Marion MJ, Nair J, Guichard Y. Formation, detection, and role in carcinogenesis of ethenobases in DNA. Drug Metab Rev 1994; 26:349-71.
30. 1 in nonhuman primates. Cancer Res 1992;52:1044-6.
31. 1-induced rat hepatic hyperplastic nodules do not exhibit a site-specific mutation within the p53 gene. Cancer Res 1993;53:9-11.
32. Duflot A, Hollstein M, Mehrotra R, Trepo C, Montesano R, Cova L. Absence of p53 mutation at codon 249 in duck hepatocellular carcinomas from the high incidence area of Qidong (China). Carcinogenesis 1994;15: 1353-7.
33. 1. Carcinogenesis 1996;17:2689-94.
34. Rivkina MB, Cullen JM, Robinson WS, Marion PL. State of the p53 gene in hepatocellular carcinomas of ground squirrels and woodchucks with past and ongoing infection with hepadnaviruses. Cancer Res 1994;54:5430-7.
35. Tokusashi Y, Fukuda I, Ogawa K. Absence of p53 mutations and various frequencies of Ki-ras exon 1 mutations in rat hepatic tumors induced by different carcinogens. Mol Carcinog 1994;10:45-51.
36. Grisham JW. Interspecies comparison of liver carcinogenesis: implications for cancer risk assessment. Carcinogenesis 1997;18:59-81.
37. Montesano R, Kirby G. Chemical carcinogens in human liver cancer. In: Brechot C, editor. Primary liver cancer: etiological and progression factors. Boca Raton (FL): CRC Press, 1994:55-77.
38. Ho YS, Cheng HT, Wang YJ, Lin JK. p53 gene mutational spectra in hepatocellular carcinomas induced by 2-acetylaminofluorene and N-nitroso-2-acetylaminofluorene in rats. Mol Carcinog 1995;13:182-90.
39. Vancutsem PM, Lazarus P, Williams GM. Frequent and specific mutations of the rat p53 gene in hepatocarcinomas induced by tamoxifen. Cancer Res 1994;54:3864-7.
40. ser induces mitotic activity but has no effect on transforming growth factor beta 1-mediated apoptosis. Cancer Res 1994;54:2064-8.
41. 1 in a shuttle vector replicating in human cells transiently expressing cytochrome P4501A2 cDNA. Mol Carcinog l992;6:140-7.
42. 1 in the human hypoxanthine guanine phosphoribosyltransferase gene. Cancer Res 1994;54:4436-41.
43. 1-induced mutations in a plasmid replicated in xeroderma pigmentosum and DNA repair proficient human cells. Cancer Res 1992;52:5668-73.
44. 1. Carcinogenesis 1996;17:2347-56.
45. 1. Proc Natl Acad Sci U S A 1983;80: 2695-8.
46. 1-DNA adduct. Proc Natl Acad Sci U S A 1996;93:1535-9.
47. 1 with guanines in different DNA sequences. Biochemistry 1988;27:472-81.
48. 1-DNA interactions. Proc Natl Acad Sci U S A 1983;80:6-10.
49. Puisieux A, Lim S, Groopman J, Ozturk M. Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. Cancer Res 1991;51:6185-9.
50. 1 induces the transversion of G→T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc Natl Acad Sci U S A 1993;90:8586-90.
51. 1 and relevance to risk of human cancer. Environ Health Perspect 1996;104 Suppl 3:557-62.
52. Wild CP, Hasegawa R, Barraud L, Chutimataewin S, Chapot B, Ito N, et al. Aflatoxin-albumin adducts: a basis for comparative carcinogenesis between animals and humans. Cancer Epidemiol Biomarkers Prev 1996;5:179-89.
53. 1. Proc Natl Acad Sci U S A 1995;92:2384-7.
54. Denissenko MF, Pao A, Tang M, Pfeifer GP. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 1996;274:430-2.
55. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994;265:346-55.
56. Adler V, Pincus MR, Minamoto T, Fuchs SY, Bluth MJ, Brandt-Rauf PW, et al. Conformation-dependent phosphorylation of p53. Proc Natl Acad Sci U S A 1997;94:1686-91.
57. Katagiri T, Nakamura Y, Miki Y. Mutations in the BRCA2 gene in hepatocellular carcinomas. Cancer Res 1996;56:4575-7.
58. Murakami Y, Hayashi K, Hirohashi S, Sekiya T. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res 1991;51:5520-5.
59. Tabor E. Tumor suppressor genes, growth factor genes, and oncogenes in hepatitis B virus-associated hepatocellular carcinoma. J Med Virol 1994; 42:357-65.
60. Tahara H, Nakanishi T, Kitamoto M, Nakashio R, Shay JW, Tahara E, et al. Telomerase activity in human liver tissues: comparison between chronic liver disease and hepatocellular carcinomas. Cancer Res 1995;55:2734-6.
61. (61 ) Murray A, Hunt T, editors. The cell cycle: an introduction. Oxford: Oxford University Press. 1993.
62. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
63. Lasko D, Cavenee W, Nordenskjold M. Loss of constitutional heterozy-gosity in human cancer. Annu Rev Genet 1991;25:281-314.
64. Montesano R, Hollstein M, Hainaut P. Genetic alterations in esophagcal cancer and their relevance to etiology and pathogenesis: a review. lnt J Cancer 1996;69:225-35.
65. Aguilar F, Harris CC, Sun T, Hollstein M, Cerutti P. Geographic variation of p53 mutational profile in nonmalignant human liver. Science 1994;264: 1317-9.
66. Wild CP, Rasheed FN, Jawla MF, Hall AJ, Jansen LA, Montesano R. In-utero exposure to aflatoxin in west Africa [letter]. Lancet 1991;337: 1602.
67. Bah E, Hall AJ, Inskip HM. The first 2 years of the Gambian National Cancer Registry. Br J Cancer 1990;62:647-50.
68. Viviani S, Jack A, Bah E, Montesano R. Hepatocellular carcinoma: a preventable cancer. Epidemiol Prev 1997;21:129-36.
69. Koulibaly M, Kabba IS, Cisse A, Diallo SB, Diallo MB, Keita N, et al. Cancer incidence in Conakry, Guinea: first results from the Cancer Registry 1992-1995. lnt J Cancer 1997;70:39-45.
70. Parkin DM, Vizcaino AP, Skinner ME, Ndhlovu A. Cancer patterns and risk factors in the African population of southwestern Zimbabwe, 1963-1977. Cancer Epidemiol Biomarkers Prev 1994;3:537-47.
71. 1 treatment of hepatitis B virus transgenic mice, but not in spontaneously arising tumours. Carcinogenesis 1997;18:633-9.
72. 1 metabolism in hepatitis B virus transgenic mice. Mol Carcinog 1994;11:74-80.
73. Chemin I, Takahashi S, Belloc C, Lang MA, Ando K, Guidotti LG, et al. Differential induction of carcinogen metabolizing enzymes in a transgenic mouse model of fulminant hepatitis. Hepatology 1996;24:649-56.
74. Graef E, Caselmann WH, Wells J, Koshy R. Insertional activation of mevalonate kinase by hepatitis B virus DNA in a human hepatoma cell line. Oncogene 1994;9:81-7.
75. Puisieux A, Ji J, Guillot C, Legros Y, Soussi T, Isselbacher K, et al. p53-mediated cellular response to DNA damage in cells with replicative hepatitis B virus. Proc Natl Acad Sci U S A 1995;92:1342-6.
76. Wang XW, Forrester K, Yen H, Feitelson MA, Gu JR, Harris CC. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci U S A 1994;91:2230-4.
77. Henkler F, Waseem N, Golding MH, Alison MR, Koshy R. Mutant p53 but not hepatitis B virus X protein is present in hepatitis B virus-related human hepatocellular carcinoma. Cancer Res 1995:55:6084-91.
78. Truant R, Antunovic J, Greenblatt J, Prives C, Cromlish JA. Direct interaction of the hepatitis B virus HBx protein with p53 leads to inhibition by HBx of p53 response element-directed transactivation. J Virol 1995;69: 1851-9.
79. Greenblatt MS, Feitelson MA, Zhu M, Bennett WP, Welsh JA, Jones R, et al. Integrity of p53 in hepatitis Bxantigen-positive and -negative hepatocellular carcinomas. Cancer Res 1997;57:426-32.
80. Harris CC, Sun T. Multifactoral etiology of human liver cancer. Carcinogenesis 1984;5:697-701.
81. Hall AJ, Inskip HM, Loik F, Chotard J, Jawara M, Vall Mayans M, et al. Hepatitis B vaccine in the expanded programme of immunisation: The Gambian experience. The Gambia Hepatitis Study Group. Lancet 1989;1: 1057-9.
82. Fortuin M, Chotard J, Jack AD, Maine NP, Mendy M, Hall AJ, et al. Efficacy of hepatitis B vaccine in the Gambian expanded programme on immunisation. Lancet 1993;341:1129-31.
83. Hall AJ, Roberston RL, Crivelli PE, Lowe Y, Inskip H, Snow SK, et al. Cost-effectiveness of hepatitis B vaccine in The Gambia. Trans R Soc Trop Med Hyg 1993;87:333-6.
84. Denning DW. Aflatoxin and human disease. Adverse Drug React Acute Poisoning Rev 1987;6:175-209.
85. 1-induced hepatocarcinogenesis in F344 rats by 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (oltipraz): predictive role for short-term molecular dosimetry. Cancer Res 1991;51:5501-6.
86. Jacobson LP, Zhang BC, Zhu YR, Wang JB, Wu Y, Zhang QN, et al. Oltipraz chemoprevention trial in Qidong, People's Republic of China: study design and clinical outcomes. Cancer Epidemiol Biomarkers Prev 1997;6:257-65.
87. Phillips TD, Clement BA, Park DL. Approaches to reduction of aflatoxins in foods and feeds. In: Eaton DA, Groopman JD, editors. The toxicology of aflatoxins: human health, veterinary and agricultural significance. New York: Academic Press, 1994:383-406.
88. Compton JA, Tyler PS, Hindmarsh PS, Golob P, Boxall RA, Haines CP. Reducing losses in small farm grain storage in the tropics. Trop Sci 1993; 33:283-318.
89. Bhatnagar D, Cleveland TE, Cotty PJ. Mycological aspects of aflatoxin formation. In: Eaton DA, Groopman JD, editors. The toxicology of aflatoxins: human health, veterinary and agricultural significance. New York: Academic Press, 1994:327-46.
90. Yu SZ. Primary prevention of hepatocellular carcinoma. J Gastroenterol Hepatol 1995;10:674-82.
91. Coursaget P, Depril N, Chabaud M, Nandi R, Mayelo V, LeCann P, et al. High prevalence of mutations at codon 249 of the p53 gene in hepatocellular carcinomas from Senegal. Br J Cancer 1993;67:1395-7.
92. Hayward NK, Walker GJ, Graham W, Cooksley E. Hepatocellular carcinoma mutation [letter]. Nature 1991;352:764.
93. Parkin DM, Muir CS, Whelan SL, Gao YT, Ferley J, Powell J, editors. Cancer incidence in five continents, vol 1. Lyon (France): IARC, 1992.